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Review
Neglected and endemic zoonoses
Ian Maudlin*, Mark Charles Eisler and Susan Christina Welburn
Centre for Infectious Diseases, College of Medicine and Veterinary Medicine, University of Edinburgh,
Summerhall, Edinburgh EH9 1QH, UK
Endemic zoonoses are found throughout the developing world, wherever people live in close
proximity to their animals, affecting not only the health of poor people but often also their
livelihoods through the health of their livestock. Unlike newly emerging zoonoses that attract the
attention of the developed world, these endemic zoonoses are by comparison neglected. This is,
in part, a consequence of under-reporting, resulting in underestimation of their global burden,
which in turn artificially downgrades their importance in the eyes of administrators and funding
agencies. The development of cheap and effective vaccines is no guarantee that these endemic dis-
eases will be eliminated in the near future. However, simply increasing awareness about their causes
and how they may be prevented—often with very simple technologies—could reduce the incidence
of many endemic zoonoses. Sustainable control of zoonoses is reliant on surveillance, but, as with
other public-sector animal health services, this is rarely implemented in the developing world, not
least because of the lack of sufficiently cheap diagnostics. Public–private partnerships have already
provided advocacy for human disease control and could be equally effective in addressing endemic
zoonoses.
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1. INTRODUCTION
(a) The nature of neglect
The United Nations Millennium Summit agreed on
the Millennium Development Goals (MDGs) in
September 2000. The aim was to halve the proportion
of people whose income is less than a dollar a day and
halve the proportion of people suffering from hunger
by 2015. This remains a formidable undertaking;
more than a billion people in the developing world
live on less than a dollar a day. There were eight
such goals: to eradicate extreme poverty and hunger;
achieve universal primary education; promote gender
equality and empower women; reduce child mortality;
improve maternal health; ensure environmental
sustainability; develop a global partnership for
development; and, of most relevance to the present
review, goal number six: to ‘combat HIV and AIDS,
malaria and other diseases’. The Global Fund (http://
www.theglobalfund.org) was created to finance the
fight against AIDS, tuberculosis (TB) and malaria,
diseases estimated to kill over six million people each
year. To date US $11.3 billion has been committed
for the fund to support interventions against these
‘big three’ diseases.
It is interesting to ask how the big three came to
dominate the global health agenda. The answer lies
in health economics, which has as its lodestar the
DALY—the disability-adjusted life year; DALYs are a
time-based measure that adds together years of life
lost owing to premature mortality with the equivalent
number of years of life lived with disability or illness
(Reithinger 2008). The WHO Global Burden
of Disease (GBD) project ‘draws on a wide range of
data sources to quantify global and regional effects
of diseases, injuries and risk factors on population
health’; the overall burden of disease is assessed
using the DALY (http://www.who.int/healthinfo/
global_burden_disease/en/). A glance at the leading
causes of burden of disease in the African region
shows that the top disease is HIV/AIDS (46.7 million
DALYs), with malaria fourth (30.9 million DALYs)
and TB eighth (10.8 million DALYs); in all the big
three cause 23.5 per cent of the disease burden as
measured by DALYs in the region. It is easy to see
why AIDS, TB and malaria have monopolized the
global health agenda as it is a simple matter for those
concerned with donor funding to consult the GBD
tables and allocate resources accordingly.
However, one unintended consequence of provid-
ing such enormous sums to combat the big three has
been to effectively erase the latter part of the pledge
contained in MDG number six: to combat HIV and
AIDS, malaria and other diseases. These ‘other
diseases’ have come to be known as ‘the neglected
tropical diseases’ (NTDs). This group includes such
notorious tropical diseases as sleeping sickness, schis-
tosomiasis, river blindness, hookworm, elephantiasis
and trachoma. These diseases affect several hundred
million people and kill at least half a million annually,
yet nowadays they attract little attention from donors,
policy makers or public health officials (Molyneux
et al. 2005). The NTDs comprise 13 parasitic and bac-
terial infections, including three soil-transmitted
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helminth infections (ascariasis, hookworm infection
and trichuriasis), lymphatic filariasis, onchocerciasis,
dracunculiasis, schistosomiasis, Chagas disease,
human African trypanosomiasis (HAT), leishmaniasis,
Buruli ulcer, leprosy and trachoma. This could be
expanded to include dengue fever, the treponema-
toses, leptospirosis, strongyloidiasis, food-borne tre-
matodiases, neurocysticercosis, echinococcosis,
scabies and a number of other tropical infections. All
lead to long-term disability, which, in turn, enhances
or maintains poverty resulting from disfigurement or
other sequelae of long-term illness, impaired child-
hood growth and development, adverse outcomes of
pregnancy and reduced productive capacity (Hotez
et al. 2007).
Given the very clear relationship between these
diseases and poverty and that such poverty, as defined
by the MDGs, is a feature almost exclusively of
families living in the developing world, it is difficult
to rationalize their ‘neglect’. It becomes more puzzling
because these diseases are some of the most common
infections of people living on less than $2 per day.
Molyneux (2008) has recently suggested that the
other diseases referred to in the MDGs are ignored
by policy makers and politicians who over-focus on
targets around the big three diseases; targets which
are in any case likely to prove unattainable.
Over-reliance on the burden of disease methodology
and the DALY measure in setting health priorities has
been criticized by health economists. Mathers
et al. (2007) acknowledge that the GBD study faces
a particular challenge in relation to NTDs given the
comparative lack of information available. King &
Bertino (2008) suggest that neglect stems in large
part from the use of the DALY in policy planning.
Where hospitals and clinics are not accessible, accurate
measurements of morbidity and mortality from NTDs
are difficult to obtain and, for most sub-Saharan
African countries GBD almost certainly underesti-
mates disease burden. They conclude that the present
DALY framework needs to be revised if the GBD is to
become a valid system for determining health priorities
because the use of the DALY results in systematic
undervaluation of NTDs. King & Bertino (2008)
further suggest that the DALY is not value-free when
dealing with workers in poor rural settings.
2. EMERGING OR RE-EMERGING
ZOONOTIC DISEASES
Nearly all of the infectious diseases that are household
names have been transferred to us from domestic live-
stock diseases (e.g. influenza from pigs; May 2007); 58
per cent of the 1407 recognized species of human
pathogen are zoonotic and, of these, 177 are regarded
as emerging or re-emerging (Woolhouse & Gowtage-
Sequeria 2005). An emerging disease as defined by
WHO is one that has appeared in a population for
the first time, while a re-emerging disease may have
existed previously but is rapidly increasing in incidence
or geographical range. Although zoonotic pathogens
are the most likely source of emerging and re-emerging
infectious disease, only a small minority have caused
major epidemics in the human population (Woolhouse &
Gowtage-Sequeria 2005). The newly emerging (or
re-emerging) diseases with which we have recently
become familiar have all come from animals: bovine
spongiform encephalopathy from cattle, severe acute
respiratory syndrome from horseshoe bats, Nipah
virus from fruit bats and H5N1 avian influenza
from poultry. However, the health impact of some of
these diseases has not been great in global terms;
if we take the example of avian influenza, from
2003 to 2009 there were 413 cases reported globally
and 256 deaths (http://www.who.int/csr/disease/avian_
influenza/). Yet avian influenza is far from being a
neglected disease in terms of funding; US $1.9 billion
was pledged to control avian influenza in 2006. The
FAO Global Programme for the Progressive Control
of Avian Influenza had received (as of 25 July 2008)
US $170.5 million (http://www.fao.org/avianflu/).
These are large sums when set against the burden of
disease data and similar funding scenarios surround
the other emerging disease threats. Given the speed
at which new viral diseases can emerge and spread, it
is understandable that the global community should
remain vigilant in terms of surveillance and ensuring
trained personnel are on hand in an emergency
(Weiss & McLean 2004). These diseases are headline
grabbing simply because they pose a direct threat to
the wellbeing of the rich, but clearly they are far
from being included in the category of neglected.
3. ENDEMIC NEGLECTED ZOONOSES
‘Endemic’ zoonoses are found throughout the devel-
oping world where conditions for their maintenance
and spread exist, and they may occasionally give rise
to epidemics. Zoonoses have long been recognized
and are associated with people living in close proximity
to their animals. They affect not only the health of
people in the poorest communities but also their liveli-
hoods by lowering the productivity or even causing the
death of their livestock. Unlike the emerging zoonoses,
the endemic zoonoses fall very much into the category
of neglected diseases and, as a result, some are now
re-emerging health problems.
A number of recent reports from international
organizations have focused on the problem of endemic
zoonoses. The joint World Health Organisation and
the Department for International Development
(DFID) UK Animal Health Programme meeting
held in Geneva in September 2005 (WHO 2006)
drew attention to the relationship between poverty
and the emergence or re-emergence of neglected
zoonotic diseases particularly: anthrax, bovine TB,
brucellosis, cysticercosis, cystic echinococcus, rabies and
HAT. The European Technology Platform for Global
Animal Health (http://www.ifaheurope.org/EUPlatform/)
has also recognized the importance of neglected
zoonoses. In 2005, the European Parliament adopted
a resolution on ‘Major and Neglected Diseases in
Developing Countries’, regretting ‘the lack of R&D
into diseases that almost exclusively affect poor people
in developing countries’ (European Parliament 2005).
This resolution identified the following zoonotic diseases
as being of particular concern: leishmaniasis, HAT, TB,
Chagas disease, cysticercosis and neurocysticercosis, but
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also called for the Commission to broaden its approach
to include other neglected diseases. Such a list would
include anthrax, rabies and brucellosis, generally
regarded as neglected and also major causes of ill
health in the poorest communities in developing
countries in Africa, Latin America and Asia. Of the 27
infectious diseases listed in the WHO GDB table, 20
can be classified as zoonoses on the basis of
documented natural transmission between animals and
humans.
Food-borne diseases afflict almost half of the
world’s population at any given time, yet there is
very little information in most countries on the
spread of food-borne zoonotic infections among the
human population. Brucellosis, bovine TB, some
parasitic diseases and salmonellosis are of greatest
importance. It is not the purpose of this review to
cover all zoonotic diseases, but rather to discuss a
number of endemic diseases and consider why they
remain a constraint to the livelihoods of the poor in
the developing world.
4. THE BURDEN OF ENDEMIC NEGLECTED
ZOONOSES
The burden of the endemic zoonoses is usually greatly
underestimated and, as with the non-zoonotic NTDs,
this has serious consequences in terms of funding for
both research and control initiatives. Diagnostics play
a significant role in the problems of underestimation
of disease. Many zoonotic diseases are notoriously dif-
ficult to diagnose as they are often confused with other
diseases; for example, where malaria is present, fevers
owing to brucellosis may be misdiagnosed. There may
simply be no reliable and cheap diagnostic test
available. In HAT, the screening test used for the
chronic, non-zoonotic form of the disease (caused by
Trypanosoma gambiense) does not work for zoonotic
trypanosomiasis (caused by Trypanosoma rhodesiense).
Few hospitals in the developing world have the
capacity to distinguish between bovine TB and
human TB. The result is that estimates of the inci-
dence and burden imposed by the neglected endemic
zoonoses seldom reflect their real importance in the
communities in which they occur.
The burden of endemic zoonoses falls particularly
heavily on the poor as they are often forced to live in
close contact with their animals and so are more
likely to become infected from these disease reservoirs.
Once infected, the poor are less likely to have access to
and receive proper treatment. The poor are particu-
larly affected by failure to diagnose their problems;
livestock keepers often live in remote rural areas
and may not be able to afford the time and money
for repeated visits to a health centre. The burden of
looking after a seriously ill family member may push
the household further into poverty and illness or
death of a breadwinner can be devastating for rural
households. Moreover, the impact of these diseases is
compounded in poor households where zoonoses
affect both people and animals; because poor people
keep fewer animals, they will suffer disproportionally
from the illness or death of their livestock. Livestock
are often central to survival strategies in poor
households as they may be sold to meet emergency
expenditures—such as school fees, treatment and
hospitalization of family members or food in times of
shortage (WHO 2006).
As with other neglected diseases, attempts to calcu-
late a global burden for the neglected zoonoses are
likely to result in underestimates. As King & Bertino
(2008) concluded: ‘for most sub-Saharan African
countries, GDB burden has been extrapolated from
scant data taken from other locations, meaning esti-
mates will be only approximate with a strong tendency
towards underestimation of disease burden’—in other
words, these estimates are simply, in their opinion,
wrong. However, efforts have been made recently to
improve on the global estimates of disease burden for
three of the endemic zoonoses, HAT, echinoccocosis
and rabies, using mathematical modelling to estimate
the extent of under-reporting (table 1).
(a) Sleeping sickness
The problems of under-reporting of diseases endemic
among the rural poor are well illustrated by attempts to
calculate the burden of disease for sleeping sickness.
There are two forms of sleeping sickness: the chronic
gambiense and acute rhodesiense forms; only the acute
form is a strictly zoonotic disease. The causal agent
of zoonotic sleeping sickness, Trypanosoma brucei
rhodesiense, infects humans and wild animals, but in
recent years cattle have been found to be the most
important reservoir in east and southern Africa
(Fe`vre et al. 2001). Untreated, the disease is always
fatal in humans, but has little or no effect on the pro-
ductivity of indigenous cattle. A study in Uganda
found that an astonishing 92 per cent of sleeping sick-
ness deaths are not reported (Odiit et al. 2005). When
considering relative costs to the local health system,
sleeping sickness cases occupy more patient admission
time than all other infectious diseases other than
malaria; severe malaria accounting for approximately
40 per cent of hospital days and HAT 30 per cent.
The true burden of HAT is poorly reflected in many
existing assessments (Fe`vre et al. 2008).
(b) Cystic echinococcosis
Cystic echinococcosis (CE) is an emerging zoonotic
parasitic disease throughout the world. Hydatid dis-
ease is a condition of livestock and humans that
arises from eating infective eggs of the cestode Echino-
coccus granulosus. Dogs are the primary definitive hosts
of the parasite, with livestock acting as intermediate
hosts and humans as aberrant intermediate hosts.
CE not only causes severe disease and possible
death in humans, but, unlike sleeping sickness, also
causes production losses in livestock. Recently,
Budke et al. (2006), in a groundbreaking study, esti-
mated the global burden of CE in both humans and
livestock, taking into account under-reporting.
Human-associated annual economic losses adjusted for
under-reporting (including medical costs, wage losses
and post-operative deaths) are estimated at US $1.9
billion and livestock losses US $2.1 billion.
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(c) Rabies
Despite its notoriety as a fatal zoonotic disease and
that effective and economical control measures are
available, rabies remains a neglected disease in the
developing world. Hard data on incidence of rabies
are difficult to obtain and under-reporting is a signifi-
cant factor. To quantify the burden of rabies in Africa
and Asia and to allow for under-reporting, Knobel
et al. (2005) developed an elegant predictive model
based on the numbers of dog bites—bites are reported
more frequently than human cases of rabies; the dog
bite data were then used to infer numbers of human
deaths. The model assumed that the human popu-
lation at risk from canine rabies was the number of
people living in areas where the dog population was
sufficient to maintain the disease endemically. The
threshold density for rabies persistence was calculated
to be 4.5 dogs km22. Using this model, it was calcu-
lated that there were over 55 000 human deaths from
rabies per year in Africa and Asia, leading to a total
DALY score of 1.7 million, and it was calculated that
the total global cost of rabies was US $583 million.
These costs are borne almost entirely by people in
the developing world where more than 99 per cent of
all fatalities from this disease occur (WHO 1998).
Apart from the three diseases for which detailed
global burdens have been calculated to allow for
under-reporting, attempts to assess the impact of
other neglected zoonoses have been proved difficult
for a variety of reasons, best illustrated by the following
examples.
(d) Bovine tuberculosis
Mycobacterium tuberculosis is the most common form of
human TB and is one of the big three killer diseases
worldwide. Bovine TB, in contrast, is now a very
rare disease in the West; for example, in the UK
since 1990, there has been only one case of indigenous
humanMycobacterium bovis infection recently acquired
from an animal source. Most cases of zoonotic TB are
attributed in the UK, to either (i) reactivation of long-
standing latent infections acquired before adoption of
milk pasteurization, or (ii) infections contracted
abroad (de la Rua-Domenech 2006). However, in
the developing world where it is transmitted zoonoti-
cally by drinking un-boiled milk and from the close
contact of humans with their livestock, M. bovis may
contribute significantly to the human epidemic
(Cosivi et al. 1995). In a study of a district of Tanzania,
M. bovis was isolated from 4 per cent of cases of pul-
monary TB (Cleaveland et al. 2007); this compares
with between 0.5 and 1.5 per cent of all the culture-
confirmed TB cases in industrialized countries (de la
Rua-Domenech 2006).
(e) Chagas disease
Chagas disease is the most important parasitic disease
of the Americas and, like other NTDs, is associated
with poverty. Caused by Trypanosoma cruzi, with reser-
voirs in dogs and a range of wild animal hosts, Chagas
disease is mainly transmitted by triatomine bugs, but
can also be transmitted congenitally, through blood
transfusion or organ transplantation, and through the
ingestion of contaminated food or fluids. Most
infected people do not know that they have become
infected, as the symptoms are benign in the initial
acute stage, after which the disease may be asympto-
matic for many years (Tarleton et al. 2007). Because
of this long asymptomatic phase, Chagas disease
is considered a ‘silent killer’ (Maguire 2006), and
it is difficult to estimate the true burden of disease.
It is estimated that there are up to 15 million existing
cases of Chagas disease, with 50 000–200 000 new
infections occurring each year.
(f) Leishmaniasis
Leishmaniasis is considered the third most important
vector-borne disease globally, with an estimated 350
million people at risk in 88 countries, 12 million
cases worldwide and around 50 000 deaths every
year (WHO 2004). Leishmaniasis is not a single dis-
ease but rather a complex of vector-borne diseases
caused by over 20 species of Leishmania. The leishma-
niases can be roughly divided into two groups of
diseases: visceral (a chronic systemic disease that can
be fatal if left untreated) and cutaneous (causing
non-fatal but often extensive skin ulceration). How-
ever, when it comes to assessing the burden imposed
by these diseases, the picture is not so clear. WHO
data indicate that the leishmaniases contribute an esti-
mated 2.4 million DALYs (WHO 2004) and while
these figures are regularly quoted, there are questions
over their validity. Bern et al. (2008) suggest that cur-
rent methods of assessing disease burden fail to
account for the variation in clinical presentation and
distribution of the disease, demanding intense medical
interventions within small foci. As with other neg-
lected diseases, reliable data (on incidence, duration
and impact of the various syndromes associated with
leishmaniasis) are lacking, and it is generally agreed
that the disease burden widely quoted for leishmania-
sis is inaccurate and out of date (Bern et al. 2008;
Reithinger 2008).
Table 1. Ten leading causes of burden of disease (DALYs)
in the African region (from WHO 2004) compared with the
three endemic zoonotic diseases for which detailed global
burdens have been calculated to allow for under-reporting.
DALYs (millions)
disease or injury
1a HIV/AIDS 46.7
2 lower respiratory infections 42.2
3 diarrhoeal diseases 32.2
4a malaria 30.9
5 neonatal infections 13.4
6 birth asphyxia and birth trauma 13.4
7 prematurity and low birth weight 11.3
8a tuberculosis 10.8
9 road traffic accidents 7.2
10 protein-energy malnutrition 7.1
selected endemic zoonoses
rabies (Africa and Asia) 1.7
HAT 1.3
cystic echinococcus (global) 0.3
aThe big three diseases.
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(g) Anthrax
Human cases of anthrax, caused by Bacillus anthracis,
are associated with infections in sheep, goats or cattle
or exposure to contaminated animal products includ-
ing wool, hides or carcasses. Pasture contamination
is the source of most animal cases in endemic
countries. Global estimates of disease burden are not
given for anthrax as WHO considers that anthrax ‘is
not a major public-health problem in the world
today, although occasional epidemics do occur’. How-
ever, because of its potential for use as a biological
weapon, anthrax is now the focus of much research
to develop improved vaccines. In contrast to the fear
that mention of this disease in the developed world
provokes because of its bio-terrorist potential, its role
in causing illness in poor livestock-keeping commu-
nities and sudden deaths in their herds and flocks is
largely ignored (WHO 2006).
(h) Cysticercosis
Cysticercosis is caused by ingestion of Taenia solium
eggs dispersed by a human carrier, the primary inter-
mediate host being the pig. Human cysticercosis is
associated with poverty and is endemic in South and
Central America, China, the Indian subcontinent
and southeast Asia and sub-Saharan Africa. Neurocys-
ticercosis is the most important neurological disease of
parasitic origin in humans and the leading cause of
late-onset epilepsy in areas where T. solium is endemic.
When cysticercosis is associated with epilepsy, the
burden of disease will dramatically increase owing to
the social stigmatization and discrimination which
can follow and which may be a barrier to diagnosis
and treatment. As neurocysticercosis cases tend to be
found in clusters, the epilepsy related to it can result
in a particularly high socio-economic burden for
poor families in the endemic areas (WHO 2003).
It has been estimated that worldwide around 2.5
million people are infected with T. solium and that
every year 50 000 deaths are caused by neurocysticer-
cosis (Mafojane et al. 2003). The global burden of
symptomatic cysticercosis in the 75 million people
living in the endemic zone in Latin America was
estimated to amount to 400 000 cases (Bern et al.
1999). Prevalence of cysticercosis in pigs in Latin
America varies from less than 2 per cent to more
than 75 per cent, with an average of 17 per cent
(Pawlowski et al. 2005). Following an increase in pig
production in smallholder farms, neurocysticercosis
is an emerging public health problem in eastern
Africa, with up to 45 per cent of pigs infected in
some villages in Uganda; in many other countries,
cysticercosis rates in pigs are around 10 per cent
(Phiri et al. 2003). In most Asian countries, accurate
data on T. solium is scarce (Singh et al. 2002), but
the disease is known to occur frequently in parts of
Indonesia, China, India and Vietnam (Pawlowski
et al. 2005).
5. PROSPECTS FOR CONTROL OF
NEGLECTED ZOONOSES
It is not our intention in this review to cover all the
efforts that have been or are being made to control
the neglected zoonoses but rather to consider some
examples of control programmes and note the lessons
learned from them. There is a temptation when con-
sidering control of diseases affecting the poor to opt
for the ‘big push’—global solutions that, while desir-
able, have little chance of effective implementation
given the socio-economic conditions surrounding
their epidemiology. The current tendency among aid
agencies is to talk of the ‘eradication’ of diseases; for
example, the eradication of malaria is now considered
by some to be an achievable goal.1 There is of course
the well-documented example of eradication, in the
proper sense of the term, of smallpox (declared
eradicated 1980), and polio has been eliminated in
high-income and middle-income countries. The
Global Rinderpest Eradication Programme is of more
relevance to the present review; the whole of Asia is
thought to have been disease-free since 2000 and
most of Africa is also now free from the disease.
According to the FAO ‘There is no known technical
reason why eradication of rinderpest should not now
be achieved’ (http://www.fao.org/Ag/againfo/programmes/
en/grep/home.html). What these rare examples of
eradication have in common is that the diseases are
caused by viruses, for which technically superb vaccines
have been developed. Eradication of rinderpest was
made possible by the development of a most effective
vaccine by Walter Plowright in the 1950s; this vaccine
was subsequently modified to deal with the problem of
maintaining a cold chain in the tropics (House &
Mariner 1996). This potential for global eradication
is a feature that sets some vaccines apart and attracts
the attention of economists as on-going costs are
eliminated (Beutels et al. 2008). However, even when
excellent vaccines are available, this is no guarantee
that elimination or eradication is easily achieved. For
example, rabies kills 55 000 people every year mainly
in Africa and Asia, despite there being very effective
vaccines available for humans, dogs and even for wild-
life. Vaccines for foxes have been proved very effective
in eliminating rabies from the wildlife reservoir in
western Europe (Smith et al. 2008), but extending
this scheme to the whole of the current EU member
states would prove costly (E10M to E16M; Freuling
et al. 2008). Dog-transmitted rabies is the greatest
threat, and in order to prevent the transmission of
rabies in a dog population, it is thought necessary to
vaccinate a minimum of 60–70% of dogs. Even
countries with sufficient resources do not often meet
and sustain these rates. One reason for such failure
might be that dog owners feel that it is too expensive
to vaccinate their pets. It was estimated in 1998 that
the cost of vaccinating dogs in developing countries,
where more than 99 per cent of all human deaths
from rabies occur, ranged from US $1.19 in the
Philippines to US $2.70 in Malawi (Meltzer &
Rupprecht 1998); in communities living on $1 per
day, dog vaccination would not be lightly undertaken.
To address this problem, the Alliance for Rabies
Control (http://www.rabiescontrol.net/) was established
in 2005 to raise awareness about the continued
presence of this neglected disease, support rabies
control programmes and promote educational
initiatives.
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Control and eradication programmes for brucellosis
have been successfully implemented within the
European Union (Godfroid & Ka¨sbohrer 2002), but
brucellosis remains an important disease in sub-
Saharan Africa. The incidence is the highest in
pastoral production systems and decreases as herd
size and size of landholding decrease (McDermott &
Arimib 2002). A recent study has shown that most
cases in Kampala, Uganda, resulted from consump-
tion of raw milk transported from peri-urban and
rural areas of Kampala and/or dairy production areas
outside Kampala (Makita et al. 2008). The most
rational approach for preventing human brucellosis is
to control infection in animals. Although there are
effective vaccines for use in cattle and goats, control
efforts in poor endemic areas have failed mainly
because of inadequate infrastructure and funding. To
be effective, control measures should continue over a
prolonged period, complemented with a monitoring
system; such systems are difficult to sustain once
the number of cases begins to decrease (Franco
et al. 2007).
For many neglected diseases, there are no effective
vaccines available, making elimination a formidable
task. This has its origins in the biology of the causative
organisms; beyond the viruses (and some bacteria)
producing effective and safe vaccines has not proved
easy. The vaccines effective against protozoal diseases
in animals, such as theilerosis and avian coccidiosis,
involve exposure to virulent or attenuated parasites
so that immunity to natural infection is established
early in life ( Jenkins 2001). Among the zoonotic pro-
tozoa, the trypanosomes offer a particularly salutary
tale of the fruitless search for vaccines. Expert opinion
is now agreed that a vaccine for sleeping sickness is
highly unlikely because these parasites make many
thousands of antigenic variants, allowing them to
evade the host immune response (Stuart et al. 2008).
Public–private partnerships (PPPs) have been set up
to improve the diagnosis (Foundation for Innovative
Diagnostics: http://www.finddiagnostics.org) and treat-
ment of neglected diseases, including sleeping sickness
(Drugs for Neglected Diseases initiative: http://www.
dndi.org).
The importance of the animal reservoir in
controlling Rhodesian sleeping sickness has long
been recognized, and the simplistic response to this
insight—destroying wild animal hosts—was neither a
successful nor an acceptable solution. We have only
recently been able to assess the importance of the
domestic animal reservoir in sleeping sickness with
the validation of a molecular marker (SRA gene) for
the identification of human infective parasites
(Welburn et al. 2001). Studies of endemic foci in
Uganda have revealed just how important the domestic
reservoir can be, with up to 40 per cent of cattle carry-
ing T. brucei rhodesiense (Fe`vre et al. 2001). Given the
importance of the animal reservoir in Rhodesian sleep-
ing sickness, vector control is easily the best control
option (Welburn et al. 2006). The enormous cost of
tsetse control programmes meant they became unsus-
tainable if the goal of elimination was not reached.
There are recent examples of effective elimination
of geographically isolated tsetse populations or
populations on the ecological limits of tsetse
distribution, such as the sterile insect project on
Unguja Island, Zanzibar (Vreysen et al. 2000), and
the aerial spraying of the Okavango Delta in Botswana
(Kgori et al. 2006). The Pan African Tsetse and
Trypanosomosis Eradication Campaign (http://www.
who.int/trypanosomiasis_african/partners/pattec/en/
index.html) was established in 2000 with support from
the African Development Bank to deal with trypanoso-
miasis in general in Africa rather than to tackle human
sleeping sickness. However, if isolation of a tsetse
population is not feasible, then reinvasion is a constant
threat raising questions of economic sustainability,
let alone the desirability of adopting tsetse elimination
as a goal (Hargrove 2003; Enserink 2007).
The development of innovative tools to trap and kill
tsetse flies has moved the focus of tsetse control from
grandiose elimination schemes to local control inter-
ventions involving communities and the efforts of
farmers themselves. Treating host animals directly
with insecticide became a practical proposition with
the introduction of long-lasting formulations of syn-
thetic pyrethroids to be poured on or sprayed on
cattle. Recent research has shown that it is not necess-
ary to treat the whole animal but only the parts of
cattle on which tsetse preferentially feed—the legs
and the belly (Torr et al. 2007); this restricted appli-
cation technology (RAP) has brought trypanosomiasis
control within the reach of poor farmers in Africa at a
cost of around US 2 cents/animal/treatment. A PPP—
The Stamp Out Sleeping Sickness campaign: http://
www.sleepingsickness.org/—aims to control the north-
ward spread of Rhodesian sleeping sickness in Uganda
(Picozzi et al. 2005) using RAP combined with trypa-
nocidal drugs.
The ‘Southern Cone’ initiative to eliminate Chagas
disease also employed a very simple technique to elim-
inate the insect vector of disease; spraying houses with
insecticide had a dramatic effect on transmission rates
in the southern part of South America (Dias et al.
2002) because the only vector, Triatoma infestans, is
an obligate human feeder and is restricted to human
habitation. However, this approach may prove difficult
to replicate elsewhere in Latin America where there are
many different vector species, each with distinct feed-
ing, infestation behaviour patterns and wild reservoirs
(Tarleton et al. 2007).
Despite substantial efforts, no effective vaccine is
available for leishmaniasis (Kedzierski et al. 2006).
First-generation candidate vaccines against leishmania-
sis, prepared using inactivated whole parasites, have
recently undergone clinical trials. Although these
studies gave some indication of protection, the trials
were an overall failure (Noazin et al. 2008). The Leish-
mania donovani ‘complex’ is now thought to comprise
only two species, Leishmania infantum and L. donovani,
which are responsible for visceral leishmaniasis (VL;
Lukes et al. 2007). Dogs are the major reservoir of
L. infantum in Brazil, but direct treatment of the
canine reservoir is seldom effective; consequently the
Ministry of Health and the Ministry of Agriculture,
Livestock and Food Supply have recently prohibited
the treatment of canine VL in Brazil (Dantas-Torres
2008). Control of VL in Brazil has instead focused
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on control of the sandfly vector by residual insecticide
spraying and culling of positive dogs. Although
effective in urban areas with high concentrations of
sandflies, residual spraying of insecticides is no
longer tenable in most situations. Effectiveness of
culling may be limited by the long interval between
diagnosis and dog removal, the sensitivity of diagnostic
tests and the natural objection of the dog owner to the
cull (Moreira et al. 2004). Moreover, there is a very
high turnover of dogs by replacement in Brazil, and
dog culling as a control strategy for VL is no longer
considered effective (Nunes et al. 2008).
The introduction of deltamethrin-impregnated dog
collars in several countries is a novel method of leish-
maniasis control that has met with varying levels of
success. A very significant reduction in canine inci-
dence (over 80%) has been demonstrated in trials of
treated dog collars in Italy (Foglia Manzillo et al.
2006; Ferroglio et al. 2008). Following a field trial
in Brazil, mathematical modelling suggested that
community-wide use of treated dog collars should be
more effective than the currently practised dog culling
strategy especially where transmission rates are high;
impact of collaring is dependent on collar coverage
and also the rate of loss of collars (Reithinger et al.
2004). Monthly application of pour-on insecticides
has also been shown to be effective in reducing
canine incidence in Italy (Ferroglio et al. 2008) and
Brazil (Giffoni et al. 2002). Interestingly, it has been
shown in Nepal that increased bed-net usage could
also decrease the incidence of VL (Bern et al. 2000).
Dogs are thought to act as disease reservoir for VL
in the Horn of Africa but, as with other neglected
diseases in Africa, poverty, poor housing, crowded
conditions, lack of bed nets and collapse of healthcare
systems all intensify the spread of VL (Bern et al.
2008). Elimination of VL remains a formidable
undertaking in the developing world, requiring
integrated control and treatment programmes ( Joshi
et al. 2008) and may well be a pipe dream at present
( Joshi et al. 2006).
Given the relatively uncomplicated epidemiology of
T. solium, elimination or even eradication might seem a
reasonable and even feasible goal. However, as the
simplest solution to this problem is the provision of
clean water and sanitation combined with veterinary
sanitary measures, such as enforced meat inspection
and treatment of infected animals, the reality is
formidable. The size of the task becomes clear when
we examine global data on water and sanitation;
WHO estimated in 2002 (http://www.who.int/water_
sanitation_health/publications/facts2004/en/index.html)
that 1.1 billion people (17% of the global population)
lacked access to improved water sources, and in
sub-Saharan Africa, 42 per cent of the population was
without improved water. At the same time, 2.6 billion
people lacked access to improved sanitation; this
represented 42 per cent of the world’s population, and
in sub-Saharan Africa, sanitation coverage is a mere
36 per cent. Of more relevance to cysticercosis
transmission, only 31 per cent of the rural inhabitants
in developing countries had access to improved
sanitation, as opposed to 73 per cent of urban
dwellers.
There have been advances in the laboratory diagno-
sis of T. solium infections using immunodiagnostics
(Garcia et al. 2000; Pawlowski et al. 2005). Detection
of the presence of tapeworms is useful for control
interventions as removal of the adult tapeworm
breaks the transmission cycle. Diagnosis of adult tape-
worms relies on the detection of parasite antigens in
faeces (coproantigens), and such tests have been
shown to have good specificity and sensitivity (Allan
et al. 2003). Vaccines based on recombinant parasite
antigens have been developed recently for use in pigs
to prevent T. solium transmission (Lightowlers et al.
2003). While pig vaccines may prove useful in
commercial settings, take-up of such vaccines by
poor farmers in rural areas where pigs are left free to
run and feed on waste seems unlikely. Treatment of
human T. solium carriers with praziquantel would be
the simplest and most effective method of control
and has been used in mass treatment programmes in
China and Latin America (Pawlowski et al. 2005).
Despite progress in operational research, global eradi-
cation of T. solium is thought to be unlikely in the near
future (Pawlowski et al. 2005).
As with cysticercosis, there have been improvements
in the diagnosis and treatment of human and animal
CE, the diagnosis of canine echinococcosis and
vaccination against E. granulosus in animals. Control
programmes against hydatidosis have been
implemented in several endemic countries (Craig &
Larrieu 2006). Despite some success in island states
(e.g. Iceland), it is acknowledged that elimination of
human CE is a formidable task and achieving such a
goal, even in the most favourable environments, may
take up to 20 years (Craig et al. 2007).
6. DISCUSSION
We have seen that neglect, in terms of disease control,
has come about in part as an unintended consequence
of adoption of a system of prioritization and hence
funding that, while logical, is not universally accepted
as being either fair or sensible. When we turn to the
endemic zoonoses of the developing world, they are
best described as the ‘more neglected diseases’. This
has come about largely owing to the difficulty in defin-
ing the burden of these diseases, which are subject to
gross under-reporting. The frequent division of
responsibility for the control of zoonotic infections
between medical and veterinary authorities provides
a further barrier to sustainable control.
There is also a political dimension to prioritization,
in that provider interest may also play a part. Shiffman
(2006) suggests that when a disease is perceived to be a
threat to the people of rich countries or when pharma-
ceutical companies see the disease as a source of
potential sales, donors are more likely to pay attention.
Trade and industrial interests may increasingly influ-
ence the tackling of global health problems (Ollila
2005) so that NTDs are given a low priority simply
because they offer negligible marketable opportunities
(Boutayeb 2007). Neglect of tropical diseases may be
connected to the fact that these diseases do not pose
any major threat to rich countries and no powerful
interest groups have mobilized around them.
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Canning (2006) argues that the overall burden of
disease should not be the criterion for priority setting,
but that cost-effective interventions should be priori-
tized. Such a cost-benefit approach, combining
health and economic benefits, would allow the health
sector to present arguments to policy makers based
on the rate of return on investment rather than tables
of DALYs. While many people find objectionable the
assignment of a monetary value to health, many
health interventions in low-income countries have
exceptionally high rankings in terms of cost-benefit
ratios. Canning (2006) suggests that interventions
against ‘neglected’ tropical diseases should be viewed
as investments in human capital and form an integral
part of global poverty reduction.
There is also a very powerful utilitarian argument
put forward by Molyneux (2008) in suggesting that
many of the neglected diseases represent ‘low-hanging
fruit’ for control and elimination, yet donors ignore
such opportunities despite the availability of cheap or
donated drugs and ample evidence that such interven-
tions are effective. There is support from King &
Bertino (2008) for this view, calculating that the
application of the DALY in policy estimates in effect
discounts the utility of comprehensively treating
NTDs. Molyneux (2008) backs up his utilitarian arg-
ument by considering the biology of neglected diseases;
the reproductive lifespan of the causative organisms of
some neglected diseases or their vectors is long:
Wuchereria bancrofti (4–6 years); Onchocerca volvulus
(12–14 years); triatomine bugs (vectors of T. cruzi;
approx. 2 years); Guinea worm (Dracunculus
medinensis; 1 year to reach maturity). These organisms
are either macro-parasites, have long-lived vectors, or
are slow growing as in leprosy. Molyneux (2008) con-
trasts successes in controlling chronic biologically
stable infections with the difficulty of controlling
malaria, TB and HIV/AIDS. The big three, with
their inherently different biology, incur problems
caused by the rapid evolution of drug resistance and
the relatively high cost both of existing drugs and of
the development of affordable alternative products.
Moreover, the likelihood that drug resistance and
insecticide resistance will develop in diseases caused
by macro-parasites or macro-vectors is small by
comparison with that in malaria, TB and HIV/AIDS.
As the organisms responsible for NTDs have little
capacity to change, controlling them is often within
the capacity of local health systems as constant revision
of control strategies is unnecessary. Some of the neg-
lected endemic zoonoses we have considered meet
Molyneux’s (2008) utilitarian criteria. For example,
T. brucei rhodesiense is transmitted by the tsetse fly—a
macro-vector reproducing very slowly, particularly
susceptible to insecticides with no sign of insecticide
resistance emerging (Maudlin 2006). It is no
surprise that a simple and cheap insecticide-based
methodology has been shown to be effective in
controlling sleeping sickness in Uganda (http://www.
sleepingsickness.org/).
The most positive and effective response to neglect
of the diseases affecting poor people in the developing
world have been for interested parties to form partner-
ships, fundraise and provide advocacy for the control
of these diseases. Successful public–private partner-
ships have been formed for the control of ‘worms’
(e.g. The Global Programme to Eliminate Lymphatic
Filariasis—http://www.filariasis.org/—and The Global
Network for NTDs—http://globalnetwork.org/).
Advocacy for neglected diseases has been improved
by the foundation of PLoS NTDs (http://www.
plosntds.org/). The key to the success of the global
chemotherapy-based control programmes has been
the availability of simple and effective drugs such as
praziquantel (Lammie et al. 2006), which could also
be used effectively for control of zoonotic cysticercosis
regionally (Pawlowski et al. 2005). However, as with
schistosomiasis (Fenwick 2006), a sustainable
reduction in transmission of cysticercosis will be
achieved only by improving health education, training,
hygiene behaviour, water supply and sanitation.
The availability of cheap and effective vaccines is no
guarantee that a disease is in danger of extinction, as
we have seen in the case of rabies. Even in poor regions
where canine rabies continues to be highly endemic,
simply increasing awareness about the cause of the dis-
ease and how it may be prevented could reduce its
incidence (Briggs & Hanlon 2007). Health education
has also proved effective in controlling T. solium
transmission in Mexico and, most importantly,
independently of direct treatment interventions (Sarti
et al. 1997).
What cysticercosis and sleeping sickness have in
common is the prerequisite that human and animal
health interventions are integrated, underlining the
need for a ‘one medicine’ approach to human and
animal health (Zinsstag et al. 2005) and particularly
the need to integrate data on human and animal
health (Singer & Ryff 2007).
Control of endemic zoonotic diseases is reliant on
surveillance but, as with other public-sector animal
health services, surveillance in sub-Saharan Africa is
rarely implemented outside southern Africa. Brucello-
sis, for example, is often ignored in humans, and most
cases go undiagnosed and untreated (McDermott &
Arimib 2002). This is a serious constraint shared
with other endemic zoonoses such as sleeping sickness,
which could be met by more effective monitoring sys-
tems; this in turn is predicated on the development of
easy to use diagnostics that must be made available
very cheaply if they are ever to be more than research
tools.
Finally we should consider whether elimination is
always the best option when considering how to deal
with endemic diseases in the developing world.
Feachem & Sabot (2008) have suggested that this
strategy of disease elimination might have the unin-
tended consequence of encouraging donors to invest
in elimination programmes at the expense of under-
resourced control efforts. Feachem & Sabot (2008)
question what interventions should be used in areas
with weak health systems, particularly in sub-Saharan
Africa, and how much elimination will actually cost.
This dilemma is perhaps best illustrated by efforts to
deal with sleeping sickness over the last century:
whether tsetse should be controlled or eradicated
and if so, how this should be achieved. Hargrove
(2003) gets to the heart of the matter when he suggests
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that this may come down simply to the power of the
different interest groups involved; the perceived benefit
of eradicating tsetse depends on the extent to which
the flies either upset, or appear to protect, the distinc-
tive type of land use beloved by each lobby, and
because the people and institutions that recommend
attacking the fly often prefer the particular control
technique that they themselves have developed or
refined, or are best able to afford. We may note
that the poor farmer, at risk from disease and loss of
livelihood, is rarely involved in this debate.
This tension, between the respective merits of con-
trol and elimination strategies, is reflected more
generally in differences at a macro-level aired by
development economists. For example, Sachs (2005)
has argued that if the developed countries increased
their foreign aid substantially, the world could eliminate
extreme poverty by 2025. By contrast, Easterly (2006)
suggests the developed world should free itself from
such Panglossian goals and concentrate on simple
things that can be done well: modest interventions,
small-scale programmes with built-in feedback. Given
this logic, it is encouraging from the viewpoint of con-
trolling endemic diseases that Easterly (2006) notes
that foreign aid successes are found more frequently
in public health than in other sectors and suggests
that this is due to the immediate feedback that health
programme beneficiaries give to programme workers.
Development experts are agreed that every child has a
right to a life free from hunger disease and suffering and
that, in the case of the world’s poor, this is clearly not
happening. However, as Easterly (2001) concludes, ‘it
is much easier to describe the problems facing poor
countries than it is to come up with workable solutions
to their poverty’; dealing with the neglected diseases is
no exception. One thing is clear—setting health priorities
by fashion is best avoided (May 2007).
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ENDNOTE
1We should note here that eradication and elimination are often
confused. Elimination is the reduction to zero of the incidence of a
disease in a defined geographical area as a result of deliberate efforts.
Eradication is the permanent reduction to zero of the worldwide
incidence of infection as a result of deliberate efforts. Importantly,
elimination demands continued efforts to prevent re-establishment
while intervention efforts are no longer needed if eradication is
achieved (Molyneux et al. 2004).
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